UMDF Power Surge 2020 – online event

GenSight Biologics reports final REALITY natural history study results confirming poor spontaneous recovery for LHON patients with ND4 mutation

GenSight Biologics reports sustained efficacy and safety among LHON patients three years after LUMEVOQ® treatment

GenSight Biologics to Host LUMEVOQ® Key Opinion Leader Call on July 9, 2020

KOL Call on LUMEVOQ® for the Treatment of Leber Hereditary Optic Neuropathy (LHON)

2020 ARVO Annual Meeting, Baltimore (MD), US – cancelled

2020 AAN Annual Meeting, Toronto, Canada – canceled due to COVID-19

GenSight Biologics Reports Cash Position as of March 31, 2020 and Provides Operational Update

GenSight Biologics on Track to Submit LUMEVOQ® for European Approval in September 2020 Following Pre-Submission Meeting with EMA

GenSight Biologics Provides Update on Operations in the Context of COVID-19